Emergent Medical Partners

Emergent Medical Partners exclusively targets seed and Series A stage companies. The firm focuses on the translational gap, where a technology has proof-of-concept but requires significant regulatory, clinical, or reimbursement expertise to reach commercialization. This stage-specific focus allows the firm to lead or co-lead rounds before other institutional capital enters.

The firm concentrates on three core verticals: traditional medical devices requiring FDA clearance, digital health platforms with clear regulatory or reimbursement pathways, and innovative healthcare service models. Within medical devices, the firm has a track record in cardiovascular, neuromodulation, and surgical technologies, while avoiding biopharmaceuticals and diagnostic platforms with uncertain regulatory endpoints.

Dr. Thomas Fogarty's status as an active surgeon and prolific medical device inventor — with over 165 patents — allows the firm to conduct technical due diligence rooted in clinical practice rather than purely financial analysis. This means the partnership spends less time on abstract market sizing and more time evaluating product-user fit, procedural adoption friction, and realistic regulatory timelines, which can be a key differentiator for founders seeking informed investors.

The firm has raised six core funds dedicated to early-stage medical technology investing. The most recent vehicle, Emergent Medical Partners VI, held its final close in October 2022 above its target (per the firm's official communications). Across all funds, the partnership has managed over $300 million in committed capital.